 Amicus Therapeutics Inc NASDAQ: FOLD has announced additional results from a Phase 12 clinical study of AT-GAA in adult patients with Pompe disease. Study participants treated with AT-GAA for up to 36 months showed persistent and durable effects on six-minute walk test 6MWT. 